AAMU
JNCE

Amundi Asset Management US’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Amundi Asset Management US’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,166
Closed -$29K – 1701
2020
Q1 		$29K Buy
+6,166
New +$35.5K ﹤0.01% 1495

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Amundi Asset Management US's JNCE Position: Q2 2020 in Review

Amundi Asset Management US sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2020, closing a stake of 6,166 shares — an estimated $29K sold.

Amundi Asset Management US first reported a position in JNCE in Q1 2020 and held it in 1 quarter. The position peaked at $29K in Q1 2020. 90 funds tracked by Wall St. Rank hold JNCE as of Q2 2020.

  • Amundi Asset Management US reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 6,166 Jounce Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $29K.
  • Amundi Asset Management US first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Amundi Asset Management US's Jounce Therapeutics, Inc. Common Stock position peaked at $29K in Q1 2020.
  • 90 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Amundi Asset Management US's 13F filing for Q2 2020, filed 14 Aug 2020.